AbbVie Invests $11B in Immunology

AbbVie has acquired Apogee Therapeutics in an $11 billion deal to expand its immunology portfolio, notably targeting autoimmune conditions with Apogee's experimental drug zumilokibart. The company aims to bolster its growth amid declining Humira sales, with the new drug showing promising results in clinical trials. Separately, healthcare innovation startup Cadence reports saving Medicare approximately $2.7 million weekly by using AI to monitor and manage chronic diseases, improving patient outcomes and reducing costs.

articleDetails.fontSize.sizeحجم النص

تنويه: هذا ملخص تم إنشاؤه بواسطة الذكاء الاصطناعي

عرض المقال بالكامل